PHASE 2 RANDOMIZED DOUBLE-BLIND PLACEBOCONTROLLED
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
Reltectimod is a synthetic peptide antagonist that is being developed for treatment of sepsis-associated acute kidney injury (SA-AKI). This study will compare the rates of complete recovery (alive, free of dialysis and return of serum creatinine to less than150% of reference baseline; equivalent to acute kidney disease (AKD) category 0) at Day 14 between the Reltecimod-treated patients and the placebo-treated patients.
Details
| Condition | TBD |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | 03403751 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.